Valuation: Beam Therapeutics Inc.

Market Cap 2.63B 2.36B 2.16B 1.97B 3.71B 247B 3.83B 26.01B 10.37B 132B 9.88B 9.67B 417B P/E 2026 *
-5.72x
P/E 2027 * -5.1x
Enterprise Value 1.74B 1.56B 1.43B 1.3B 2.46B 164B 2.53B 17.21B 6.86B 87.38B 6.54B 6.4B 276B EV / Sales 2026 *
45.1x
EV / Sales 2027 * 71.7x
Free-Float
98.8%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Beam Therapeutics Inc.

1 day+2.78%
1 week+5.57%
Current month+0.29%
1 month+6.26%
3 months+0.11%
6 months-13.98%
Current year-1.48%
1 week 24.88
Extreme 24.88
28
1 month 23.16
Extreme 23.16
29.76
Current year 21.63
Extreme 21.63
38.26
1 year 20.23
Extreme 20.23
38.26
3 years 13.52
Extreme 13.525
49.5
5 years 13.52
Extreme 13.525
97.7
10 years 13
Extreme 13
138.52
Manager TitleAgeSince
Chief Executive Officer 48 01/01/2017
Director of Finance/CFO 48 19/12/2024
President 57 24/01/2020
Director TitleAgeSince
Director/Board Member 48 01/01/2017
Director/Board Member 75 01/05/2018
Director/Board Member 56 10/10/2019
Date Insider Type Main position Quantity % Market Cap. Importance
16/10/26 Exercice

Chief Executive Officer

75,000 0.0726%
1/10/26 Sell

Controller/Auditor

-187 0.0002%
24/9/26 Don

Chairperson

-123,407 0.1195%
Change 5-day change 1-year change 3-year change Capi.($)
+3.10%+5.57%+26.14%+22.96% 2.63B
+2.24%+5.83%+58.47%+65.65% 66.7B
+4.46%+8.72%+14.39%+85.10% 56.88B
0.00%+2.38%+24.27%+95.64% 56.53B
+2.11%+15.36%+26.59%+119.86% 46.49B
+1.18%+6.84%+29.61%+43.88% 44.8B
+2.65%+5.97%+217.89%+896.05% 41.59B
-0.47%+9.60%+27.53%+52.88% 35.35B
+3.80%-0.14%+96.91%+68.25% 33.29B
+0.16%+5.33%-40.01%+391.63% 25.1B
Average +1.90%+2.66%+48.18%+184.19% 40.94B
Weighted average by Cap. +1.93%+3.92%+51.25%+179.45%

Financials

2026 *2027 *
Net sales 38.6M 34.62M 31.64M 28.88M 54.42M 3.63B 56.13M 381M 152M 1.94B 145M 142M 6.11B 31.37M 28.14M 25.72M 23.47M 44.23M 2.95B 45.62M 310M 124M 1.57B 118M 115M 4.97B
Net income -480M -431M -394M -360M -677M -45.17B -699M -4.75B -1.89B -24.1B -1.8B -1.76B -76.08B -560M -502M -459M -419M -789M -52.62B -814M -5.53B -2.21B -28.08B -2.1B -2.06B -88.64B
Net Debt -890M -798M -730M -666M -1.25B -83.68B -1.29B -8.8B -3.51B -44.65B -3.34B -3.27B -141B -382M -343M -313M -286M -539M -35.94B -556M -3.78B -1.51B -19.18B -1.44B -1.4B -60.54B
Projected Income Statement - Annual - Beam Therapeutics Inc.
Logo Beam Therapeutics Inc.
Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302 and BEAM-301. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents designed to offer a one-time treatment to correct the E342K point mutation (PiZZ genotype).
Employees
557
Date Price Change Volume
10/11/26 USD 27.27 +3.26% 254,502
06/11/26 USD 26.41 +2.09% 1,984,920
05/11/26 USD 25.87 -6.91% 2,991,345
04/11/26 USD 27.79 +5.55% 1,348,236
03/11/26 USD 26.33 +1.78% 1,434,270
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - Beam Therapeutics Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
26.41USD
Average target price
49.62USD
Spread / Average Target
+87.87%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Beam Therapeutics Inc.
  1. Stock Market
  2. Stocks
  3. BEAM Stock